who's who

3 Houston innovators to know this week

This week's innovators to know include Samantha Snabes and Charlotte Craff of Re:3D and Andrew Bruce of Data Gumbo. Photos courtesy

Editor's note: In today's Monday roundup of Houston innovators to know as we start a new week, we introduce you to two forward-thinking 3D printing experts and a startup founder with fresh funds to tackle smart contracts in the industrial sector.

Samantha Snabes and Charlotte Craff of Re:3D

Re:3D's Samantha Snabes, co-founder, and Charlotte Craff, who oversees community relations, join the Houston Innovators Podcast to share what makes their company different and where the industry is headed. Photos courtesy of Re:3D

Houston-based Re:3D has no shortage of exciting business opportunities — from developing bigger and better 3D printers to hosting tours in their lab. But, one thing co-founder Samantha Snabes and community expert Charlotte Craff are proud of is their partnership with local organizations to create PPE for the People, a movement that helped create and provide PPE for workers in need.

"As the pandemic continued, the data was emerging that people of color in Black and Brown communities and underserved communities were at greater risk of critical illness from COVID-19," Craff says on the podcast. "We wanted to specifically target people of color who were working as Texas opened back up its doors." Read more.

Andrew Bruce, CEO of Data Gumbo

Andrew bruce's growing Houston blockchain startup has raised $4 million to go toward supporting sales. Photo courtesy of Data Gumbo

While the intersection of dropping oil prices earlier this year and a global pandemic provided its own set of challenges, one thing Andrew Bruce of Data Gumbo Corp. observed is that it was more important than ever for the energy industry to focus on their bottom line. And that's exactly what his technology allows to happen.

"The opportunity in all this is companies have got to cut expenses," Andrew Bruce, CEO and founder, tells InnovationMap. "What's happened to us is our sales have absolutely exploded — in a good way. We have a huge number of leads, and we have to be able to deliver on those leads."

Last month, Data Gumbo closed a $4 million series B funding round led by new investor L37, which has operations in the Bay Area and in Houston. The round also saw contribution from returning investors Equinor Ventures and Saudi Aramco Energy Venture. Read more.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted